[go: up one dir, main page]

SG11201810116VA - Exosomes comprising therapeutic polypeptides - Google Patents

Exosomes comprising therapeutic polypeptides

Info

Publication number
SG11201810116VA
SG11201810116VA SG11201810116VA SG11201810116VA SG11201810116VA SG 11201810116V A SG11201810116V A SG 11201810116VA SG 11201810116V A SG11201810116V A SG 11201810116VA SG 11201810116V A SG11201810116V A SG 11201810116VA SG 11201810116V A SG11201810116V A SG 11201810116VA
Authority
SG
Singapore
Prior art keywords
international
oxford
pct
road
polypeptide
Prior art date
Application number
SG11201810116VA
Inventor
Justin Hean
Imre Mager
Matthew Wood
Andaloussi Samir El
Oscar WIKLANDER
Joel NORDIN
Original Assignee
Evox Therapeutics Ltd
Oxford Univ Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evox Therapeutics Ltd, Oxford Univ Innovation filed Critical Evox Therapeutics Ltd
Publication of SG11201810116VA publication Critical patent/SG11201810116VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01021—Beta-glucosidase (3.2.1.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111111111111111 010111010 11111 0 01 010 11111 001 0111 100 110 111110 1111 0111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\"1 WO 2017/203260 Al 30 November 2017 (30.11.2017) WIPO I PCT (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, A61K 41/00 (2006.01) A61K 47/64 (2017.01) KM, ML, MR, NE, SN, TD, TG). A61K 47/65 (2017.01) (21) International Application Number: Published: PCT/GB2017/051479 — with international search report (Art. 21(3)) (22) International Filing Date: 25 May 2017 (25.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1609216.5 25 May 2016 (25.05.2016) GB (71) Applicants: EVOX THERAPEUTICS LTD [GB/GB]; 2nd Floor, King Charles House, Park End Street, Ox- ford OX1 9QT (GB). OXFORD UNIVERSITY INNO- VATION [GB/GB]; Buxton Court, 3 West Way, Oxford OX2 OJB (GB). (72) Inventors: HEAN, Justin; 17 Aldrich Road, Oxford OX2 _ 7SS (GB). MAGER, Imre; 19 Hadow Road, Oxford OX2 OJW (GB). WOOD, Matthew; 13 Leckford Road, Oxford = OX2 6HY (GB). EL ANDALOUSSI, Samir; Enrisvagen 14, 14131 Huddinge (SE). WIKLANDER, Oscar; Greta = Garbos vag 21B, 16940 Solna (SE). NORDIN, Joel; Hilde- vergsvagen 12, 11762 Stockholm (SE). — = Agent: HEARE-ROWLANDS, Tanya; Cooley (UK) (74) = LLP, Dashwood, 69 Old Broad Street, London EC2M 1QS = = (GB). Designated States (unless otherwise indicated, for every (81) = kind of national available): AE, AG, AL, AM, protection = AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, = = DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, = KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, = = SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, = — TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = — (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, = GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, — 1-1 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, .4 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 0 ei MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, en © (54) Title: EXOSOMES COMPRISING THERAPEUTIC POLYPEPTIDES ei ---- (57) : The present invention pertains to an inventive release mechanism for extracellular vesicle (EV)-mediated intracellular IN and intramembrane delivery of therapeutic polypeptides. More specifically, the invention relates to EVs comprising polypeptide con- 0 structs which comprise a therapeutic polypeptide releasably attached to an exosomal polypeptide. Furthermore, the present invention N pertains to manufacturing methods, pharmaceutical compositions, medical uses and applications, and various other embodiments re- n lated to the inventive EVs.
SG11201810116VA 2016-05-25 2017-05-25 Exosomes comprising therapeutic polypeptides SG11201810116VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1609216.5A GB201609216D0 (en) 2016-05-25 2016-05-25 Exosomes comprising therapeutic polypeptides
PCT/GB2017/051479 WO2017203260A1 (en) 2016-05-25 2017-05-25 Exosomes comprising therapeutic polypeptides

Publications (1)

Publication Number Publication Date
SG11201810116VA true SG11201810116VA (en) 2018-12-28

Family

ID=56369954

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810116VA SG11201810116VA (en) 2016-05-25 2017-05-25 Exosomes comprising therapeutic polypeptides

Country Status (17)

Country Link
US (2) US11534499B2 (en)
EP (3) EP4523706A3 (en)
JP (3) JP6855567B2 (en)
KR (1) KR102253731B1 (en)
CN (2) CN116103241A (en)
AU (1) AU2017270932B2 (en)
BR (1) BR112018074229A2 (en)
CA (1) CA3024020C (en)
DK (1) DK3463465T3 (en)
ES (1) ES2836553T3 (en)
GB (1) GB201609216D0 (en)
MX (1) MX378381B (en)
PT (1) PT3463465T (en)
RU (1) RU2737732C2 (en)
SG (1) SG11201810116VA (en)
WO (1) WO2017203260A1 (en)
ZA (1) ZA201807945B (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
GB201609216D0 (en) 2016-05-25 2016-07-06 Evox Therapeutics And Isis Innovation Ltd Exosomes comprising therapeutic polypeptides
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
KR102776166B1 (en) 2017-08-07 2025-03-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 Platform for generating safe cell therapeutics
GB2568255A (en) * 2017-11-08 2019-05-15 Evox Therapeutics Ltd Exosomes comprising RNA therapeutics
US12473598B2 (en) 2018-03-28 2025-11-18 Board Of Regents, The University Of Texas System Identification of epigenetic alterations in DNA isolated from exosomes
CA3097558A1 (en) * 2018-04-19 2019-10-24 Board Of Regents, The University Of Texas System Therapeutic modulation of tumor suppressors using exosomes
CN108753822A (en) * 2018-06-20 2018-11-06 中国人民解放军第四军医大学 Deliver the expression vector and its preparation method and application of pattern of fusion rna binding protein
CN108753806A (en) * 2018-06-20 2018-11-06 中国人民解放军第四军医大学 Enhancing target RNA is loaded into expression vector and its construction method and the application of the fusion protein of excretion body
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
WO2020041725A1 (en) * 2018-08-24 2020-02-27 University Of Delaware Extracellular vesicles as biomarkers and therapeutics for neuromuscular disorders
CN109293745A (en) * 2018-09-04 2019-02-01 暨南大学 A carrier protein, recombinant expression vector, exosome and preparation method and application
CN109321596B (en) * 2018-09-05 2021-12-17 暨南大学 Preparation method and application of protein-entrapped exosome
CN109234237B (en) * 2018-09-30 2020-08-07 中国人民解放军第四军医大学 Exosome loaded with ABCA1mRNA and construction method and application thereof
CN113272426A (en) * 2018-11-16 2021-08-17 医福斯治疗有限公司 Extracellular vesicles for replacement of urea cycle proteins and nucleic acids
CA3120701A1 (en) * 2018-11-21 2020-05-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods and materials for reducing age-related striated muscle and cognitive decline
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020152298A1 (en) * 2019-01-24 2020-07-30 Fundació Hospital Universitari Vall D'hebron - Institut De Recerca Method for producing enzymes
US20220249373A1 (en) * 2019-02-04 2022-08-11 Codiak Biosciences, Inc. Membrane protein scaffolds for exosome engineering
CN114127285B (en) 2019-03-19 2024-09-10 布罗德研究所股份有限公司 Methods and compositions for editing nucleotide sequences
SG11202109587TA (en) * 2019-03-21 2021-10-28 Codiak Biosciences Inc Extracellular vesicle conjugates and uses thereof
EP3956349A1 (en) 2019-04-17 2022-02-23 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US20240024220A1 (en) * 2019-05-11 2024-01-25 Youngsuk Yi Neurotoxin compositions and methods
US20220259617A1 (en) 2019-06-13 2022-08-18 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
CA3144267A1 (en) * 2019-06-21 2020-12-24 Entelexo Biotherapeutics Inc. Platforms, compositions, and methods for therapeutics delivery
KR102125567B1 (en) * 2019-07-02 2020-06-22 한양대학교 에리카산학협력단 Large-Scale Production of Plant Derived Exosomes
US20220354963A1 (en) * 2019-08-14 2022-11-10 Codiak Biosciences, Inc. Extracellular vesicle linked to molecules and uses thereof
WO2021039884A1 (en) * 2019-08-28 2021-03-04 国立研究開発法人理化学研究所 Cell membrane-permeable vesicle
GB201915855D0 (en) * 2019-10-31 2019-12-18 Univ Oxford Innovation Ltd An extracellular vesicle
CN110954703A (en) * 2019-12-27 2020-04-03 杭州迪相实业有限公司 A method for simultaneous detection of exosome protein and RNA, exosome membrane protein
AU2021215935A1 (en) 2020-02-05 2022-08-25 Diadem Biotherapeutics Inc. Artificial synapses
WO2021162375A1 (en) * 2020-02-10 2021-08-19 성균관대학교산학협력단 Exosome comprising photocleavable protein, and use thereof
KR102688170B1 (en) * 2020-02-10 2024-07-24 주식회사 엑소스템텍 Exosome comprising photocleavable protein and Use thereof
EP4119166A4 (en) 2020-03-12 2024-06-05 Institute for Basic Science Composition for inducing apoptosis of cells having genomic sequence variation and method for inducing apoptosis of cells by using composition
US12472228B2 (en) 2020-03-31 2025-11-18 Ilias Biologics Inc. Use of exosome-based delivery of NF-κB inhibitors
EP4127136A4 (en) * 2020-03-31 2024-04-03 Ilias Biologics Inc. Use of exosome-based delivery of nf-kb inhibitors
WO2021223659A1 (en) * 2020-05-06 2021-11-11 Nanjing Iaso Biotherapeutics Co., Ltd. Extracellular vesicles targeting cancer cells and uses thereof
CN111569077B (en) * 2020-05-29 2021-10-26 南方医科大学 Use of Flot2 inhibitor for inhibiting osteoclast formation and/or osteoclast activity
IL300001A (en) 2020-07-24 2023-03-01 Massachusetts Gen Hospital Improved virus-like particles and methods of using them for administration to cells
RU2766707C1 (en) * 2020-11-13 2022-03-15 Федеральное государственное бюджетное образовательное учреждение высшего образования «Московский государственный университет имени М.В.Ломоносова» (МГУ) Drug for treatment of tissue fibrosis based on components of secretome of mesenchymal stromal cells, method for obtaining and applying remedy
CN112773775B (en) * 2021-01-13 2022-12-20 广东药科大学 A preparation method and application of loaded norcantharidin exosomes
WO2022158836A1 (en) * 2021-01-21 2022-07-28 주식회사 엑소코바이오 Recombinant exosome comprising fc receptor or portion thereof to which target protein or peptide is fusible, and use thereof
WO2022215078A1 (en) * 2021-04-07 2022-10-13 Ramot At Tel-Aviv University Ltd. Modified cannabinoids and uses thereof
US20240182890A1 (en) 2021-04-07 2024-06-06 Astrazeneca Ab Compositions and methods for site-specific modification
KR20230175237A (en) * 2021-04-22 2023-12-29 오하이오 스테이트 이노베이션 파운데이션 Nanocarriers targeting tumor-associated macrophages
GB202107182D0 (en) * 2021-05-19 2021-06-30 Evox Therapeutics Ltd Nanoparticle delivery system for production of engineered extracellular vesicles
WO2022264905A1 (en) 2021-06-16 2022-12-22 日本精工株式会社 Load estimating device for rolling bearing, control device for mechanical device provided with rolling bearing, load estimating method, and program
JP2024528697A (en) 2021-07-20 2024-07-30 エイジーエス・セラピューティクス・ソシエテ・パール・アクシオン・サンプリフィエ Microalgae-derived extracellular vesicles, their preparation and use
US20250115902A1 (en) 2021-10-07 2025-04-10 H.U. Group Research Institute G.K. Construct
GB2631171A (en) 2021-12-03 2024-12-25 Broad Inst Inc Compositions and methods for efficient in vivo delivery
WO2023144127A1 (en) 2022-01-31 2023-08-03 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
EP4526459A2 (en) 2022-05-17 2025-03-26 Nvelop Therapeutics, Inc. Compositions and methods for efficient in vivo delivery
WO2023232976A1 (en) 2022-06-03 2023-12-07 Ags Therapeutics Sas Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
GB202211033D0 (en) * 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process
EP4608424A1 (en) 2022-10-24 2025-09-03 AGS Therapeutics SAS Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof
CN116803424B (en) * 2023-08-24 2023-11-28 上海懿贝瑞生物医药科技有限公司 SLC17A5 gene inhibitor and application thereof
WO2025058473A1 (en) * 2023-09-14 2025-03-20 주식회사 엑소스템텍 Technology for degenerative brain disease-therapeutic protein delivery specifically to brain by using exosomes comprising degenerative brain disease-therapeutic protein
KR20250105276A (en) * 2023-12-29 2025-07-08 (주)에스엔이바이오 Extracellular vesicle loaded with neuropeptide and use thereof
WO2025172421A1 (en) 2024-02-14 2025-08-21 Astrazeneca Ab Compositions and methods for treatment of huntington's disease
WO2025176847A1 (en) 2024-02-21 2025-08-28 Ags Therapeutics Sas Ocular delivery of active agents via microalgae extracellular vesicles
WO2025196641A1 (en) * 2024-03-19 2025-09-25 Биоплатформ Гмбх Hybrid particles, method for producing same and use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834247A (en) * 1992-12-09 1998-11-10 New England Biolabs, Inc. Modified proteins comprising controllable intervening protein sequences or their elements methods of producing same and methods for purification of a target protein comprised by a modified protein
US5935822A (en) * 1995-03-21 1999-08-10 The Regents Of The University Of Colorado Product and process for membrane and soluble polypeptide segregation
GB0112687D0 (en) 2001-05-24 2001-07-18 Microbiological Res Authority Pharmaceutical use of secreted bacterial effector proteins
BRPI0816236A2 (en) 2007-08-20 2015-08-18 Oncotherapy Science Inc Cdh3 peptide and medicinal agent containing the same
CN108117584B (en) 2007-08-20 2021-08-24 肿瘤疗法科学股份有限公司 FOXM1 peptide and agents comprising FOXM1 peptide
EP2127640A1 (en) 2008-05-27 2009-12-02 Koninklijke Philips Electronics N.V. Azide modified proteins
GB201121070D0 (en) * 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
CN103205435A (en) 2013-04-11 2013-07-17 浙江大学 Method for expressing lactoferrin improved peptide LF-6 by using intein escherichia coli
US11274139B2 (en) 2013-04-12 2022-03-15 Evox Therapeutics Ltd Therapeutic delivery vesicles
JP6525971B2 (en) 2013-06-11 2019-06-05 タカラ バイオ ユーエスエー， インコーポレイテッド Protein-enriched microvesicles, methods of making and using protein-enriched microvesicles
WO2015002956A1 (en) 2013-07-01 2015-01-08 Ohio State Innovation Foundation Exosome delivery system
US10370420B2 (en) 2014-02-11 2019-08-06 The Governors Of The University Of Alberta Genetically encoded photocleavable proteins
US20170173113A1 (en) 2014-03-13 2017-06-22 Research Institute At Nationwide Children's Hospital Methods of delivering heparin binding epidermal growth factor using stem cell generated exosomes
WO2016077639A2 (en) * 2014-11-12 2016-05-19 VL27, Inc. Nanovesicular therapies
KR20160130937A (en) * 2015-05-04 2016-11-15 한국과학기술원 Process for preparing exosome loading target protein and method for loading target protein to cytosol by using exosome prepared thereby
WO2016178532A1 (en) 2015-05-04 2016-11-10 한국과학기술원 Production method for exosome comprising target protein, and method for transferring target protein into cytoplasm by using exosome produced by means of the production method
WO2017182608A1 (en) * 2016-04-22 2017-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and vaccine compositions for the treatment of b-cell malignancies
GB201609216D0 (en) * 2016-05-25 2016-07-06 Evox Therapeutics And Isis Innovation Ltd Exosomes comprising therapeutic polypeptides

Also Published As

Publication number Publication date
EP3782646B1 (en) 2024-09-25
EP3463465A1 (en) 2019-04-10
AU2017270932A1 (en) 2018-12-20
MX378381B (en) 2025-03-10
ZA201807945B (en) 2020-05-27
WO2017203260A1 (en) 2017-11-30
RU2018145738A3 (en) 2020-09-08
JP7483648B2 (en) 2024-05-15
EP3782646A1 (en) 2021-02-24
EP4523706A3 (en) 2025-05-28
AU2017270932B2 (en) 2021-04-29
CA3024020A1 (en) 2017-11-30
MX2018014509A (en) 2019-06-06
JP6855567B2 (en) 2021-04-07
CN109715211B (en) 2022-12-20
EP4523706A2 (en) 2025-03-19
US20230201370A1 (en) 2023-06-29
KR20190011279A (en) 2019-02-01
BR112018074229A2 (en) 2019-03-26
EP3463465B1 (en) 2020-10-14
DK3463465T3 (en) 2020-12-14
GB201609216D0 (en) 2016-07-06
PT3463465T (en) 2020-11-04
JP2019520852A (en) 2019-07-25
US20190167810A1 (en) 2019-06-06
US11534499B2 (en) 2022-12-27
KR102253731B1 (en) 2021-05-24
RU2737732C2 (en) 2020-12-02
JP2024103494A (en) 2024-08-01
ES2836553T3 (en) 2021-06-25
JP2021100416A (en) 2021-07-08
CN109715211A (en) 2019-05-03
RU2018145738A (en) 2020-06-25
CA3024020C (en) 2022-03-08
CN116103241A (en) 2023-05-12

Similar Documents

Publication Publication Date Title
SG11201810116VA (en) Exosomes comprising therapeutic polypeptides
SG11201811150WA (en) Ev-mediated delivery of binding protein-small molecule conjugates
SG11201811148SA (en) Cell penetrating peptide (cpp)-mediated ev loading
SG11201811152YA (en) Uses of extracellular vesicle comprising a fusion protein having fc binding capacity
SG11201811209QA (en) Oral gastroretentive formulations and uses thereof
SG11201901141WA (en) Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
SG11201805950UA (en) Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them
SG11201811149TA (en) METABOLIC DRUG LOADING OF EVs
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201811549UA (en) Boronic acid derivatives and therapeutic uses thereof
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201908075UA (en) A microneedle device
SG11201408054RA (en) Pegylated oxm variants
SG11201806485RA (en) Pyrrolobenzodiazepine conjugates
SG11201809031XA (en) Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201808221QA (en) 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors
SG11201811180PA (en) Communication methods, computer-readable media, communication devices, and servers
SG11201804223TA (en) OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF
SG11201408509PA (en) Racecadotril lipid compositions
SG11201805755SA (en) Methods of administering hepcidin
SG11201906616VA (en) Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants